S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
President of Latvia visits S.Korea's Daan Cancer Lab
Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...
Mediaiplus aims to be the Amazon of clinical trials
Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...
Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials
Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...
Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman
WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...
Global quest to find modern elixirs enters new chapter
NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...
SK Telecom to enter Australian pet clinics market in H1
South Korea’s SK Telecom Co. announced on Tuesday that it has signed a commercial contract with ATX Medical Solutions, Australia's largest m...
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
LG Chem out-licenses obesity drug candidate to US firm
LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
CGBio gets FDA approval for Novosis Putty
South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...
Peter Thiel-backed D&D Pharmatech gets preliminary nod for IPO
South Korean clinical-stage biotech D&D Pharmatech Inc. has won approval from the Korea Exchange’s preliminary review for listing on the j...
LG Elec launches new medical monitor
LG Electronics Inc. unveiled a new medical monitor on Wednesday. This monitor boasts high brightness suitable for both clinical and diagnostic purpo...
HK inno.N reveals differentiated clinical results for K-CAB
South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...
SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine
South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
NKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
Daewoong to develop eye drops for diabetic retinopathy
South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...
VaxCell Bio's treatment shows promise for advanced liver cancer
South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...
Wellmarker Bio signs worth of $528 mn tech transfer deal
Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a Europ...
Celltrion builds clinical data bank for new biosimilars
The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...
AriBio applies for Phase 3 clinical trials in China for oral dementia drug
South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...
Yungjin Pharm's new drug candidate gets Fast Track from FDA
South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...
JW Pharma to participate in S.Korea’s new drug project
South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program b...
Hanmi Pharm to start global clinical trials for immune-oncology drug
South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...
JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan
South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout t...
ABL Bio gets OK for phase 1 clinical trials for immune-oncology drug
New drug development company ABL Bio Inc. announced on Thursday that it has received approval from the Ministry of Food and Drug Safety of South Kor...
LG Chem to make first domestic 6-in-1 vaccine for infants
South Korea's LG Chem Ltd. will produce the nation's first homegrown six-in-one vaccine for infants, something that the country is entirely reliant ...
Hanmi Pharm to develop obesity drug customized for S.Korean
South Korea's Hanmi Pharmaceutical Co. plans to develop the GLP-1 class "Epeglenatide," which it received as a technology return from Sanofi S.A., i...
